Bicara Therapeutics Inc. BCAX

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
44/100
Developing

Ranked against 712 peers in Biotechnology

About Bicara Therapeutics Inc.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in … Full BCAX analysis →

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.90), providing operational cushion.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.23), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where BCAX ranks in Biotechnology

Bicara Therapeutics Inc. ranks #309 of 713 scored companies in Biotechnology by moat score — the top 43%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
305 Aptevo Therapeutics Inc. APVO 45/100 Developing
306 Orchestra BioMed Holdings, Inc. OBIO 45/100 Developing
307 IN8bio, Inc. INAB 45/100 Developing
308 Kezar Life Sciences, Inc. KZR 45/100 Developing
309 Bicara Therapeutics Inc. BCAX 44/100 Developing
310 Nutriband Inc. Warrant NTRBW 44/100 Developing
311 Cartesian Therapeutics, Inc. RNAC 44/100 Developing
312 ACELYRIN, INC. SLRN 44/100 Developing
313 Nutriband Inc. NTRB 44/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How BCAX scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 42 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 48 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding BCAX's moat

What is Bicara Therapeutics Inc.'s moat score?

Bicara Therapeutics Inc. (BCAX) scores 44 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #309 of 713 scored companies in Biotechnology, the top 43%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (48/100) and its weakest is Capital Efficiency (42/100).

How does Bicara Therapeutics Inc. compare with other Biotechnology companies?

Bicara Therapeutics Inc. ranks #309 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Kezar Life Sciences, Inc. (KZR) at 44 just above it and Nutriband Inc. Warrant (NTRBW) at 44 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Bicara Therapeutics Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Bicara Therapeutics Inc.?

The Corporate Default template measures 6 defenses, and BCAX scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (42), Resilience (48), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000